Ethiopia Confirms First Marburg Virus Disease Outbreak: 19 Cases, 64.3% Fatality Rate, and a Coordinated International Response
核心洞察
Ethiopia confirmed its first-ever Marburg virus disease (搜索) (MVD) outbreak in November 2025, centered in Jinka town, South Ethiopia Region, with 19 total cases (14 confirmed, 5 probable) and a 64.3% case fatality rate among confirmed cases.
The outbreak was declared over on 26 January 2026 after 42 consecutive days with no new cases, with over 3,800 diagnostic tests conducted and 857 contacts completing 21-day follow-up monitoring.
Investigational countermeasures deployed included the Sabin Vaccine Institute (搜索)'s cAd3-Marburg vaccine (640+ doses), Gilead's remdesivir (1,200 doses), and Mapp Biopharmaceutical (搜索)'s MBP091 monoclonal antibody, all under emergency use frameworks.
Ethiopia's Ministry of Health confirmed the country's first-ever Marburg virus disease (搜索) (MVD) outbreak on 14 November 2025, marking a significant public health emergency for the nation and the broader East African region. The outbreak was initially detected in Jinka town, South Ethiopia Region, an area bordering Kenya and South Sudan. The index case was an adult male from Jinka who was admitted to the general hospital on 23 October 2025 after developing nausea, anorexia, and abdominal cramps. As of 25 January 2026, a total of 19 cases were reported, comprising 14 laboratory-confirmed cases (including nine deaths) and five probable cases (all of whom died), alongside five recoveries. The case fatality rate among confirmed cases stood at 64.3%, falling within the 24–88% range documented in prior African MVD outbreaks.
The outbreak was declared over by Ethiopia's Ministry of Health on 26 January 2026, following 42 consecutive days—equivalent to two 21-day incubation periods—after the last laboratory-confirmed case died on 14 December 2025. More than 3,800 diagnostic tests were conducted during the outbreak period, and all 857 contacts listed for monitoring completed their 21-day follow-up. Cases were reported from Jinka, Malle, and Dasench woredas in South Ethiopia Region, as well as Hawassa in Sidama Region. One case identified in Hawassa was traced back to Jinka town and closely linked to the index case, indicating a clear epidemiological connection in the transmission chain.
Clinical Presentation and Transmission Dynamics
Patients presented with headache, high fever, abdominalgia, nausea, and watery or bloody diarrhea. Five cases exhibited hemorrhagic manifestations including epistaxis and hematemesis, consistent with multi-organ failure. MVD, caused by the Marburg virus (搜索) (MARV) and Ravn virus (RAVV) of the Filoviridae family, is a severe viral hemorrhagic fever with an average fatality rate of approximately 50%, according to the WHO. Zoonotic spillover from fruit bat reservoirs—notably Rousettus aegyptiacus—followed by person-to-person transmission via direct contact with bodily fluids represents the established transmission pathway.
Preliminary genomic analysis suggested that the detected virus strain showed similarities to those identified in previous East African outbreaks, consistent with regional lineage diversity, though detailed sequence data have not been widely released in the public domain.
Government and International Response
Ethiopian health authorities rapidly activated incident management systems at both federal and regional levels. Key response measures included deployment of a mobile high-biosafety laboratory to Jinka for timely RT-PCR confirmation, establishment of isolation and treatment centers with two designated hospitals, issuance of the first edition of Ethiopian National Guidelines for clinical management of MVD, and intensive contact tracing with risk-based monitoring.
The WHO released USD 300,000 from its contingency fund for emergencies and deployed an 11-member multidisciplinary team of technical officers with extensive experience in VHF outbreaks. Africa CDC (搜索) provided technical support and capacity building in VHF detection and sequencing. Additional international partners included the US CDC, the European Union, Germany's GIZ and Robert Koch Institute, the UK Health Security Agency, Médecins Sans Frontières, and the International Federation of Red Cross and Red Crescent Societies.
The Intergovernmental Authority on Development (IGAD), in collaboration with WHO, convened an emergency high-level meeting under the Regional Preparedness for Pandemic Response (PREPARE) initiative, with delegates from Ethiopia, Kenya, Uganda, and Djibouti attending.
Investigational Vaccines and Therapeutics
No approved or fully licensed antivirals, monoclonal antibodies, or vaccines exist specifically for MVD. However, several investigational countermeasures were deployed under emergency use frameworks. The Ethiopian Food and Drug Authority (EFDA) developed a guideline for emergency use authorization of vaccines and therapeutics for MVD (Document Number: EFDA/GDL/057).
The Sabin Vaccine Institute (搜索) delivered more than 640 doses of its experimental cAd3-Marburg vaccine to Ethiopia, with vaccine administration beginning on 08 December 2025. The vaccine, based on GSK's Chimpanzee Adenovirus Type 3 (cAd3) platform and funded by BARDA, is being evaluated in a Phase 2, open-label, randomized trial (ClinicalTrials.gov ID: NCT06620003) across two cohorts: high-risk health professionals and contacts of confirmed cases (Cohort A), and other eligible healthcare workers and contacts (Cohort B). The US Administration for Strategic Preparedness and Response (ASPR) committed up to 2,500 additional doses.
Gilead Sciences provided 1,200 doses of remdesivir under emergency use authorization, administered as a 200 mg IV loading dose followed by 100 mg IV daily for 10–14 days for treatment, or as a three-day short-course for post-exposure prophylaxis. Additionally, Mapp Biopharmaceutical (搜索)'s investigational monoclonal antibody MBP091 was delivered, with five treatment courses arriving on 5 December 2025, administered as a single IV infusion at 100 mg/kg.
Regional Risk and Ongoing Challenges
Jinka's location near international borders—approximately 80–100 km from Kenya and South Sudan—combined with high population mobility, posed significant cross-border transmission risk. The presence of Rousettus bat colonies, artisanal mining, and expanded agriculture in South Ethiopia created ongoing spillover interfaces. Ethiopia's health system faced substantial strain from concurrent outbreaks of cholera, measles, and dengue, alongside declining donor contributions and funding gaps.
Misinformation and conflicting case reports circulated widely on social media, complicating risk communication efforts and eroding public trust. The outbreak also highlighted the vulnerability of healthcare workers, with occupational exposure and nosocomial transmission documented among infected personnel.
Implications for Future Preparedness
The emergence of MVD in Ethiopia represents a pivotal moment for national and regional health security. Sustained containment will require strengthened surveillance, community engagement, cross-border collaboration, and integrated One Health approaches. Ethiopia's performance in the WHO Joint External Evaluation (JEE) for surveillance—scoring 4 out of 5 in both early warning surveillance (D2.1) and data analysis and information sharing (D2.3)—provided a foundation for the rapid detection and notification that characterized the early response. Long-term investment in resilient health systems and coordinated regional preparedness remains essential to prevent future spillover events and protect vulnerable populations.